在新诊断为淋巴瘤的患者中,治疗前的萨科佩尼亚的患病率
Acta haematologica
|April 6, 2025
概括
麻症影响3%的新诊断的淋巴瘤患者,尽管22%的患者显示肌肉质量较低. 仅仅肌肉强度可能不足以对这一群体进行查.
科学领域:
- 在瘤学瘤学.
- 老年病的医生 老年病的医生
- 临床营养学 临床营养学
背景情况:
- 标志着肌肉强度,质量和性能下降的萨尔科佩尼亚严重复杂化了癌症治疗,影响了治疗效率,患者的生活质量和生存率.
- 肉类的存在在治疗新诊断的淋巴瘤患者中构成了相当大的挑战.
- 了解sarcopenia患病率对于优化淋巴瘤患者的护理途径至关重要.
研究的目的:
- 为了确定新诊断为淋巴瘤的个体中肉类的患病率.
- 在这个患者群体中,评估萨科佩尼亚评估的不同组件的有用性.
主要方法:
- 这项研究包括了预定接受一线以环素为基础的化疗的成年患者.
- 在开始治疗之前,根据欧洲共识指导方针 (EWGSOP2) 进行了肉症查.
- 评估包括评估肌肉力量 (手握),肌肉质量 (DXA扫描) 和身体性能 (步行速度).
主要成果:
- 在69名参与者中,3%的人满足了sarcopenia的标准,其中有一个严重的sarcopenia病例.
- 很大一部分 (22%) 的肌肉质量较低,9%的手握力较低,6%的步行速度较低.
- 这些发现凸显了总体的肉症患病率与其个别组成部分之间的差异.
结论:
- 在新诊断的淋巴瘤患者中,肉类的总体患病率为3%.
- 然而,观察到较高的低肌肉质量 (22%) 的流行率,表明其作为早期指标的潜力.
- 仅仅评估肌肉强度可能不足以用于查淋巴瘤患者的肉,这表明需要进行全面评估.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


